FDA 510(k)

CAPI 3 Hb A1c, MULTI-SYSTEM Hb A1C CAPILLARY CONTROLS (2)

K号: K162281 · 2017-02-17

申请人Sebia

决定日期2017-02-17

产品代码LCP

咨询委员会HE 请注意，由于您只提供了“HE”作为输入，我无法提供完整的翻译。请提供完整的描述或文本，以便我能够进行准确的翻译。

决定实质等同

器械摘要

CAPI 3 Hb A1c, MULTI-SYSTEM Hb A1C CAPILLARY CONTROLS (2) is the device name listed in this FDA 510(k) record. The listed applicant is Sebia. It received FDA 510(k) clearance on 2017-02-17 under 510(k) number K162281. The device is classified under product code LCP. It was reviewed by the HE advisory panel. FDA Decision: Substantially Equivalent.

常见问题

What is the CAPI 3 Hb A1c, MULTI-SYSTEM Hb A1C CAPILLARY CONTROLS (2)?

CAPI 3 Hb A1c, MULTI-SYSTEM Hb A1C CAPILLARY CONTROLS (2) is a medical device that received FDA 510(k) clearance on 2017-02-17. The listed applicant is Sebia. The 510(k) number is K162281.

When did CAPI 3 Hb A1c, MULTI-SYSTEM Hb A1C CAPILLARY CONTROLS (2) receive FDA 510(k) clearance?

CAPI 3 Hb A1c, MULTI-SYSTEM Hb A1C CAPILLARY CONTROLS (2) received FDA 510(k) clearance on 2017-02-17, under 510(k) number K162281.

Who is the listed applicant for CAPI 3 Hb A1c, MULTI-SYSTEM Hb A1C CAPILLARY CONTROLS (2)?

The FDA 510(k) record lists Sebia as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for CAPI 3 Hb A1c, MULTI-SYSTEM Hb A1C CAPILLARY CONTROLS (2)?

The FDA product code for CAPI 3 Hb A1c, MULTI-SYSTEM Hb A1C CAPILLARY CONTROLS (2) is LCP.

列明Sebia为申报人的其他记录

关联记录通过名称、产品代码或其他元数据自动匹配。匹配不意味着已验证临床、科学、企业或监管关系；请查阅链接的官方来源。

K232027CAPI 3 NEONAT Hb, CAPILLARYS 3 DBS Instrument K231601FLC Kappa，FLC Lambda，FLC 控制级别 1，FLC 控制级别 2 K210623FLC Kappa，FLC Lambda，FLC 控制级别 1，FLC 控制级别 2 K203184HYDRASHIFT 2/4 isatuximab K192095CAPI 3 Immunotyping, Capillarys 3 Tera K190851HYDRASHIFT 2/4 daratumumab

查看所有 12 个设备 →

官方来源

在 FDA 数据库中查看 →

数据来源于FDA开放API。如需最新且权威的信息，请务必参考官方记录。